Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minn, H.
Right arrow Articles by Wahl, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minn, H.
Right arrow Articles by Wahl, R. L.

Radiology, Vol 196, 167-173, Copyright © 1995 by Radiological Society of North America

ARTICLES

Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET

H Minn, KR Zasadny, LE Quint and RL Wahl
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0028, USA.

PURPOSE: To study the precision of repeated 2-[fluorine-18]-fluoro-2- deoxy-D-glucose (FDG) uptake measurements at positron emission tomography (PET) in patients with primary lung cancer. MATERIALS AND METHODS: Ten patients with untreated lung cancer underwent two dynamic FDG PET examinations after a 4-hour fast within 1 week. Kinetic modeling of tumor FDG uptake was performed on the basis of a three- compartment model. The tumor concentration of F-18 (standardized uptake value calculated on the basis of predicted lean body mass [SUV-lean]) was also measured 50-60 minutes after injection of a tracer. Blood glucose, insulin, and free fatty acid levels were monitored. RESULTS: SUV-lean and the FDG influx constant Ki were measured with a mean +/- standard deviation difference of 10% +/- 7 and 10% +/- 8, respectively, over repeated PET scans. The mean difference was reduced to 6% +/- 6 and 6% +/- 5 by multiplying SUV-lean and Ki by plasma glucose concentration. CONCLUSION: SUV-lean and graphical Ki can be measured reproducibly, supporting their use in quantitative FDG PET algorithms.


This article has been cited by other articles:


Home page
 The OncologistHome page
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens
Application of PET/CT in the Development of Novel Anticancer Drugs
Oncologist, January 1, 2008; 13(1): 25 - 38.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
J. Clin. Oncol., October 20, 2007; 25(30): 4714 - 4721.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Kawada, K. Murakami, T. Sato, Y. Kojima, H. Ebi, H. Mukai, M. Tahara, K. Shimokata, and H. Minami
Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors
Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 44 - 48.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y. L. Kasamon, R. J. Jones, and R. L. Wahl
Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma
J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber and R. Figlin
Monitoring Cancer Treatment with PET/CT: Does It Make a Difference?
J. Nucl. Med., January 1, 2007; 48(1_suppl): 36S - 44S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-H. Lee, S.-H. Lee, D.-W. Kim, W. J. Kang, J.-K. Chung, S.-A. Im, T.-Y. Kim, Y. W. Kim, Y.-J. Bang, and D. S. Heo
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Clin. Cancer Res., July 15, 2006; 12(14): 4232 - 4236.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber
Positron Emission Tomography As an Imaging Biomarker
J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. K. Shankar, J. M. Hoffman, S. Bacharach, M. M. Graham, J. Karp, A. A. Lammertsma, S. Larson, D. A. Mankoff, B. A. Siegel, A. Van den Abbeele, et al.
Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
J. Nucl. Med., June 1, 2006; 47(6): 1059 - 1066.
[Full Text] [PDF]

Home page
 JNMHome page
J. R. Tseng, M. Dandekar, M. Subbarayan, Z. Cheng, J. M. Park, S. Louie, and S. S. Gambhir
Reproducibility of 3'-Deoxy-3'-18F-Fluorothymidine MicroPET Studies in Tumor Xenografts in Mice
J. Nucl. Med., November 1, 2005; 46(11): 1851 - 1857.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
J. Clin. Oncol., October 20, 2005; 23(30): 7445 - 7453.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
M. Westerterp, H. L. van Westreenen, J. B. Reitsma, O. S. Hoekstra, J. Stoker, P. Fockens, P. L. Jager, B. L. F. Van Eck-Smit, J. T. M. Plukker, J. J. B. van Lanschot, et al.
Esophageal Cancer: CT, Endoscopic US, and FDG PET for Assessment of Response to Neoadjuvant Therapy--Systematic Review
Radiology, September 1, 2005; 236(3): 841 - 851.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Dose Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Janicke, and N. Avril
Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET
J. Nucl. Med., July 1, 2005; 46(7): 1144 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Wells, R. N. Gunn, C. Steel, A. S. Ranicar, F. Brady, S. Osman, T. Jones, and P. Price
2-[11C]Thymidine Positron Emission Tomography Reproducibility in Humans
Clin. Cancer Res., June 15, 2005; 11(12): 4341 - 4347.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med., June 1, 2005; 46(6): 983 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y.-Y. Yau, W.-S. Chan, Y.-M. Tam, P. Vernon, S. Wong, M. Coel, and S. K.-F. Chu
Application of Intravenous Contrast in PET/CT: Does It Really Introduce Significant Attenuation Correction Error?
J. Nucl. Med., February 1, 2005; 46(2): 283 - 291.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Boellaard, N. C. Krak, O. S. Hoekstra, and A. A. Lammertsma
Effects of Noise, Image Resolution, and ROI Definition on the Accuracy of Standard Uptake Values: A Simulation Study
J. Nucl. Med., September 1, 2004; 45(9): 1519 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. Paquet, A. Albert, J. Foidart, and R. Hustinx
Within-Patient Variability of 18F-FDG: Standardized Uptake Values in Normal Tissues
J. Nucl. Med., May 1, 2004; 45(5): 784 - 788.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. B. Chin, P. Patel, C. Cohade, M. Ewertz, R. Wahl, and P. Ladenson
Recombinant Human Thyrotropin Stimulation of Fluoro-D-Glucose Positron Emission Tomography Uptake in Well-Differentiated Thyroid Carcinoma
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 91 - 95.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Ott, U. Fink, K. Becker, A. Stahl, H.-J. Dittler, R. Busch, H. Stein, F. Lordick, T. Link, M. Schwaiger, et al.
Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial
J. Clin. Oncol., December 15, 2003; 21(24): 4604 - 4610.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber, V. Petersen, B. Schmidt, L. Tyndale-Hines, T. Link, C. Peschel, and M. Schwaiger
Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use
J. Clin. Oncol., July 15, 2003; 21(14): 2651 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. Dizendorf, T. F. Hany, A. Buck, G. K. von Schulthess, and C. Burger
Cause and Magnitude of the Error Induced by Oral CT Contrast Agent in CT-Based Attenuation Correction of PET Emission Studies
J. Nucl. Med., May 1, 2003; 44(5): 732 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
S. J. Karlik
Visualizing Radiologic Data
Am. J. Roentgenol., March 1, 2003; 180(3): 607 - 619.
[Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
K. Dhital, C. A.B. Saunders, P. T. Seed, M. J. O'Doherty, and J. Dussek
[18F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer
Eur. J. Cardiothorac. Surg., October 1, 2000; 18(4): 425 - 428.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. A. Thie, K. F. Hubner, and G. T. Smith
The Diagnostic Utility of the Lognormal Behavior of PET Standardized Uptake Values in Tumors
J. Nucl. Med., October 1, 2000; 41(10): 1664 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Vesselle, R. A. Schmidt, J. M. Pugsley, M. Li, S. G. Kohlmyer, E. Vallières, and D. E. Wood
Lung Cancer Proliferation Correlates with [F-18]Fluorodeoxyglucose Uptake by Positron Emission Tomography
Clin. Cancer Res., October 1, 2000; 6(10): 3837 - 3844.
[Abstract] [Full Text]

Home page
 RadiologyHome page
Y. Sugawara, K. R. Zasadny, A. W. Neuhoff, and R. L. Wahl
Reevaluation of the Standardized Uptake Value for FDG: Variations with Body Weight and Methods for Correction
Radiology, November 1, 1999; 213(2): 521 - 525.
[Abstract] [Full Text]

Home page
 RadiologyHome page
Y. Sugawara, K. R. Zasadny, H. B. Grossman, I. R. Francis, M. F. Clarke, and R. L. Wahl
Germ Cell Tumor: Differentiation of Viable Tumor, Mature Teratoma, and Necrotic Tissue with FDG PET and Kinetic Modeling
Radiology, April 1, 1999; 211(1): 249 - 256.
[Abstract] [Full Text]

Home page
 BloodHome page
W. Romer, A.-R. Hanauske, S. Ziegler, R. Thodtmann, W. Weber, C. Fuchs, W. Enne, M. Herz, C. Nerl, M. Garbrecht, et al.
Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose
Blood, June 15, 1998; 91(12): 4464 - 4471.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1995 by the Radiological Society of North America.